Needham Sets Kazia Therapeutics Price Target at $27 per Share
Needham announced a $27.00-per-share price target for Kazia Therapeutics. The body also says Needham initiated coverage with a Buy rating.
Related stories
Harris Teeter Launches New Rewards World Elite Mastercard
The new card offers grocery savings and fuel discounts when shopping at Harris Teeter.
M impact | EQUITY | Oct 30, 2026, 12:01 PM UTC
Palo Alto Networks Advises Stockholders to Reject Tutanota Mini-Tender Offer
Palo Alto Networks said it received notice of an unsolicited offer by Tutanota LLC to buy up to 250,000 shares of its common stock.
H impact | EQUITY | Oct 30, 2026, 12:00 PM UTC
Dominion Energy Q3 Profit Rises to $1.160 Billion
Dominion Energy reported earnings of $1.30 per share, compared with $1.16 per share a year earlier. Profit totaled $1.160 billion, versus $1.006 billion.
M impact | EQUITY | Oct 30, 2026, 12:00 PM UTC
Simon Subsidiary Agrees to Acquire University Village
Simon said a subsidiary entered into an agreement to acquire University Village, an open-air retail property.
M impact | EQUITY | Oct 30, 2026, 12:00 PM UTC
European session market picture: S&P 500 -1.11%, Nasdaq 100 -2.59%; EUR/USD +0.14%, WTI +2.01%, LLOY leads volume
European session market picture. US index futures: S and P futures is down 1.11 percent, Nasdaq futures is down 2.59 percent, Dow futures is up 0.01 percent and Russell futures is
M impact | EQUITY | Oct 30, 2026, 12:00 PM UTC
Exxon Mobil Raises Stake in Mozambique LNG Project to 50%
Exxon Mobil increased its stake in the planned project.
M impact | EQUITY | Oct 30, 2026, 11:58 AM UTC